title: Contemporary insights into the pathogenesis and treatment of chronic myeloproliferative neoplasms.
abstract: This review is based on the deliberations at the 5th John Goldman Colloquium held in Estoril on 2nd October 2015 and the 9th post-ASH International Workshop on chronic myeloid leukemia (CML) and BCR-ABL1-negative myeloproliferative neoplasms (MPN) which took place on the 10th-11th December 2014, immediately following the 56th American Society of Hematology Annual Meeting. It has been updated since and summarizes the most recent advances in the biology and therapy of these diseases, in particular updates of genetics of MPN, novel insights from mouse MPN models, targeting CML stem cells and its niche; clinical advances include updates on JAK2 inhibitors and other therapeutic approaches to BCR-ABL1-negative MPNs, the use of alpha interferons, updates on tyrosine kinase inhibitors (TKI) randomized trials in CML, TKI cessation studies, and optimal monitoring strategies.
authors.affiliation: a Tufts University Medical Center , Boston , MA , USA ;
authors.forename: Tariq I
authors.initials: TI
authors.lastname: Mughal
authors.affiliation: b Memorial Sloan Kettering Cancer Center , New York , NY , USA ;
authors.forename: Omar
authors.initials: O
authors.lastname: Abdel-Wahab
authors.affiliation: b Memorial Sloan Kettering Cancer Center , New York , NY , USA ;
authors.forename: Raajit
authors.initials: R
authors.lastname: Rampal
authors.affiliation: c Mayo Clinic Cancer Center , Scottsdale , AZ , USA ;
authors.forename: Ruben
authors.initials: R
authors.lastname: Mesa
authors.affiliation: d Department of Hematology, Oncology, Hemostaseology, and Stem Cell Transplantation, Faculty of Medicine , RWTH Aachen University , Aachen , Germany ;
authors.forename: Steffen
authors.initials: S
authors.lastname: Koschmieder
authors.affiliation: b Memorial Sloan Kettering Cancer Center , New York , NY , USA ;
authors.forename: Ross
authors.initials: R
authors.lastname: Levine
authors.affiliation: e Hematology, Universität Heidelberg , Mannheim , Germany ;
authors.forename: Rüdiger
authors.initials: R
authors.lastname: Hehlmann
authors.affiliation: f Orbassano University Hospital , Turin , Italy ;
authors.forename: Giuseppe
authors.initials: G
authors.lastname: Saglio
authors.affiliation: g Papa Giovani XXIII Hospital and Research Center , Bergamo , Italy ;
authors.forename: Tiziano
authors.initials: T
authors.lastname: Barbui
authors.affiliation: h Chao Family Comprehensive Cancer Center, University of California Irvine , Irvine , CA , USA.
authors.forename: Richard A
authors.initials: RA
authors.lastname: Van Etten
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use; D004195:Disease Models, Animal; D020022:Genetic Predisposition to Disease; D006801:Humans; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000175:diagnosis / Q000209:etiology* / Q000628:therapy*; D051379:Mice; D058990:Molecular Targeted Therapy; D009154:Mutation; D009196:Myeloproliferative Disorders / Q000175:diagnosis / Q000209:etiology* / Q000401:mortality / Q000628:therapy*; D047428:Protein Kinase Inhibitors / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D018570:Risk Assessment; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D047428:Protein Kinase Inhibitors
keywords: Molecular genetics; myeloid leukemias and dysplasias; stem and primitive progenitor cells